D.E. Shaw & Co
AMLX icon

D.E. Shaw & Co’s Amylyx Pharmaceuticals AMLX Stock Holding History

D.E. Shaw & Co’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
174,285
+100,055
+135% +$1.55M ﹤0.01% 2808
2026
Q1 		$1.03M Buy
74,230
+1,006
+1% +$14.2K ﹤0.01% 3419
2025
Q4 		$885K Buy
73,224
+4,347
+6% +$59K ﹤0.01% 3618
2025
Q3 		$936K Sell
68,877
-82,625
-55% -$778K ﹤0.01% 3497
2025
Q2 		$971K Sell
151,502
-118,504
-44% -$576K ﹤0.01% 3251
2025
Q1 		$956K Sell
270,006
-36,738
-12% -$131K ﹤0.01% 3109
2024
Q4 		$1.16M Sell
306,744
-384,322
-56% -$1.81M ﹤0.01% 3121
2024
Q3 		$2.24M Sell
691,066
-617,115
-47% -$1.39M ﹤0.01% 2629
2024
Q2 		$2.49M Buy
1,308,181
+265,598
+25% +$515K ﹤0.01% 2463
2024
Q1 		$2.96M Buy
1,042,583
+495,618
+91% +$6.48M ﹤0.01% 2316
2023
Q4 		$8.05M Sell
546,965
-213,325
-28% -$3.27M 0.01% 1528
2023
Q3 		$13.9M Sell
760,290
-829,754
-52% -$17.5M 0.01% 1059
2023
Q2 		$34.3M Sell
1,590,044
-432,326
-21% -$11.7M 0.04% 585
2023
Q1 		$59.3M Buy
2,022,370
+638,638
+46% +$22.2M 0.06% 375
2022
Q4 		$51.1M Buy
1,383,732
+1,221,467
+753% +$43.3M 0.06% 430
2022
Q3 		$4.57M Buy
+162,265
New +$4.05M 0.01% 2196

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

D.E. Shaw & Co's AMLX Position: Q2 2026 in Review

D.E. Shaw & Co increased its Amylyx Pharmaceuticals (AMLX) stake by 135% in Q2 2026, buying an estimated $1.55M and bringing the position to 174,285 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

D.E. Shaw & Co first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. The position peaked at $59.3M in Q1 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • D.E. Shaw & Co held 174,285 shares of Amylyx Pharmaceuticals worth $3.13M as of Q2 2026.
  • D.E. Shaw & Co bought 100,055 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2808 holding.
  • D.E. Shaw & Co first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • D.E. Shaw & Co's Amylyx Pharmaceuticals position peaked at $59.3M in Q1 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.